



MEDIA RELEASE

FOR IMMEDIATE RELEASE

July 24, 2011

ITL INVENTS NEW ANTI-AGING DRUG TECHNOLOGY THAT COULD INTRODUCE NEW ERA OF MEDICINE

(Bristol, Va.) – ITL Pharma, a drug discovery and development company, has come up with a new way to treat diseases associated with aging like heart disease, cancer, Alzheimer’s disease, and Parkinson’s disease.

“Our goal is to cure diseases rather than just paste over the symptoms like many contemporary medicines,” says Dr. Keith R. Latham, President and Chief Scientist at ITL Pharma.

This new medical paradigm is called FROS Therapy. “We have discovered that normal aging and many disease processes associated with aging result from exposure to free radical/oxidative species (FROS),” says Dr. Latham. “These highly reactive chemical entities are like high velocity bullets flying through a battle field. These “bullets” can destroy normal cell components and finally cause cell death if the exposure is high enough.”

Chronic exposure to low level free radical damage results in “normal aging”. However, under certain conditions, FROS can generate their own expanding cascade of free radicals that escape the normal capacity to keep them in check. This condition is called a “free radical catastrophe”. If unchecked, this cascade causes enough cell and tissue damage, to result in cell death.

Free radicals come from infections, tumors, leaky mitochondria, radiation exposure and environmental toxins. Some people are especially long-lived because they are born with a natural genetic capacity to deal with FROS, assuming they also maintain a healthy, forgiving life-style.

A new class of diagnostic and therapeutic compounds has been developed at ITL Pharma that are designed to capture and neutralize these destructive free radical "bullets", to slow and possibly cure FROS mediated diseases like Alzheimer's, Parkinson's, inflammatory disease and heart disease.

Current treatments frequently only paste over the symptoms with no apparent mechanism for a cure. ITL's new technology could introduce a new paradigm to treat oxidative diseases and recognize a new therapeutic branch called, "Free Radical Oxidative Medicine".

Slowing the onset of FROS diseases will have an impact at many levels. When the root causes of the diseases are eliminated, natural recovery will initiate and the patients and their caregivers can regain and maintain a higher quality of life. Enhancing quality of life is the focus of these new therapies.

Improved health and higher quality of life for the senior population also translates in major savings in healthcare programs, including Medicaid and Medicare.

ITL Pharma's primary mission is to discover and bring to market cutting-edge treatments of some of today's most pervasive and long-suffering diseases, resulting in pharmacology that will revolutionize the delivery of health care and the entire pharmaceutical industry.

For more information, visit www.itlpharma.com.